Glenn Kroog is an Oncology physician affiliated with Regeneron. OpenAlex indexes 137 publications with 2,166 citations (h-index 23); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Memorial Sloan-Kettering Cancer Center
1275 York Avenue
New York, NY 10065
Telephone
646-422-4313Registry record last updated 21 Aug 2007.
Clinical trials
- Sunitinib in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer
Sponsor: Memorial Sloan Kettering Cancer Center
- A Study of RAD001 and Sunitinib in Metastatic Renal Cell Carcinoma
Sponsor: Memorial Sloan Kettering Cancer Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
NIH funding
1 NIH research award on record, funded 2003–2005 per NIH RePORTER. The latest:
- GRP Receptor Signaling: Role of the C-Terminal Domain
Albert Einstein Col of Med Yeshiva Univ
FY2005$159,300K22CA098102 - GRP Receptor Signaling: Role of the C-Terminal Domain
Albert Einstein Col of Med Yeshiva Univ
FY2004$159,300K22CA098102
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Linvoseltamab in Patients With Relapsed/Refractory Multiple Myeloma in the LINKER-MM1 Study: Longer Follow-Up and Subgroup Analyses
Clinical Lymphoma Myeloma & Leukemia
2025 - Indirect Comparison of Linvoseltamab Versus Teclistamab for the Treatment of Triple-Class Exposed Relapsed/Refractory Multiple Myeloma
Clinical Lymphoma Myeloma & Leukemia
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Robert Kimberly
Regeneron
Robert Vitti, MD
Regeneron
Thomas Uldrick, MD
Regeneron
Andrew Fontenot, MD
Regeneron
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”